Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
Jazz Pharmaceuticals announced positive second interim results from the Phase 3 HERIZON-GEA-01 trial, demonstrating that Ziihera plus chemotherapy achieved a statistically significant overall survival benefit compared to trastuzumab plus chemotherapy in first-line HER2+ advanced gastroesophageal adenocarcinoma. The trial, which enrolled 914 patients across more than 30 countries, showed an improved hazard ratio for overall survival, reinforcing Ziihera's superiority over the current standard of care.
Key figures
- Drug Name
- Ziihera (zanidatamab-hrii)
- Phase Of Trial
- Phase 3
- Countries
- more than 30
- Trial sites
- 225
- Patient count
- 914
- Safety cohort ziihera plus chemo
- 395
- Safety cohort ziihera plus chemo plus tislelizumab
- 330
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.